Additional Covenants of Codexis Sample Clauses

Additional Covenants of Codexis. Codexis hereby covenants to Merck that: 9.5.1 with respect to each In-License Agreement, Codexis shall maintain and keep each In-License Agreement in full force and effect under each In-License Agreement’s respective terms for the term of the In-Licensed IP licensed pursuant to such In-License Agreement; 9.5.2 Codexis shall not amend any such In-License Agreement in a manner that adversely affects Merck’s rights under this Agreement and/or imposes any additional obligations upon Merck not disclosed to Merck under the In-License Agreements; 9.5.3 Codexis, pursuant to the terms of the In-License Agreements, shall pay any and all annual license fees due to all Third Party licensors during the Term required to maintain each In-License Agreement; provided, however, that nothing contained herein shall require Codexis to be responsible for Losses arising from the breach of any In-License Agreements by Merck as a sublicensee; and 9.5.4 If during the Term Merck [***] concludes that one or more [***] are necessary to [***] during the Term and in the manner contemplated by Section 9.2.1, Merck shall notify Codexis in writing [***] [***] and Merck and Codexis shall [***]. If the Parties [***]. If the Parties [***]. If the Parties [***]. If the [***]. If the [***]. If the [***]. In no event will the [***].
Additional Covenants of Codexis. Codexis hereby covenants to Merck that: 9. 5.1 with respect to each In-License Agreement, Codexis shall maintain and keep each In-License Agreement in full force and effect under each In-License Agreement’s respective terms for the term of the In-Licensed IP licensed pursuant to such In-License Agreement;
Additional Covenants of Codexis. Codexis hereby covenants to Novartis that: 9.6.1 with respect to each In-License Agreement, Codexis shall maintain and keep each In-License Agreement in full force and effect under each In-License Agreement’s respective terms for the term of the In-Licensed IP licensed pursuant to such In-License Agreement; 9.6.2 Codexis shall not amend any such In-License Agreement in a manner that adversely affects Novartis’ rights under this Agreement and/or imposes any additional obligations upon Novartis not disclosed to Novartis under the In-License Agreements; 9.6.3 Codexis, pursuant to the terms of the In-License Agreements, shall pay any and all annual license fees due to all Third Party licensors during the Term required to maintain each In-License Agreement; provided, however, that nothing contained herein shall require Codexis to be responsible for Losses arising from the breach of any In-License Agreements by Novartis as a sublicensee; and